Insulin resistance with altered secretory kinetics reduced proinsulin in cystic fibrosis patients

Journal of Pediatric Gastroenterology and Nutrition

Volumn 25, Issue 2, 1997, Pages 188-193

  Holl, R W ^a,c   Wolf, A ^a   Thon, A ^b   Bernhard, M ^b   Buck, C ^a   Missel, M ^a   Heinze, E ^a   Von Der Hardt, H ^b   Teller, W M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Medical Center   (Germany)

^c Department of Pediatrics I ^*  (Germany)

Author keywords

C peptide; Cystic fibrosis; Glucose tolerance; Insulin resistance; Insulin secretion; Proinsulin

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; PROINSULIN;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADOLESCENT; BLOOD GLUCOSE; C-PEPTIDE; COHORT STUDIES; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; PROINSULIN; REFERENCE VALUES; TIME FACTORS;

EID: 0030760747     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199708000-00010     Document Type: Article

References (42)

1. Rodman HM, Doershuk CF, Roland JM. The interaction of 2 diseases: diabetes mellitus and cystic fibrosis. Medicine 1986;65:389-97.
2. Handwerger S, Roth J, Gorden P, S'Agnese P, Carpenter DF, Peter G. Glucose intolerance in cystic fibrosis. N Engl J Med 1969;281: 451-61.
3. Rosenecker J, Eichler I, Kühn L, Harms H, vonder Hardt H. Genetic determination of diabetes mellitus in patients with cystic fibrosis. J Pediatr 1995;127:441-3.
4. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. Br Med J 1995;311:655-9.
5. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992;151:684-7.
6. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994;83:849-53.
7. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988;122:373-7.
8. Sullivan MM, Denning CR. Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics 1989;84:642-9.
9. Dodge JA, Morrison G. Diabetes mellitus in cystic fibrosis: a review. J R Soc Med 1992;85(Suppl 19):25-8.
10. Holl RW, Heinze E, Wolf A, Rank M, Teller WM. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr 1995;154:356-61.
11. Thon A, Holl RW, Wolf A, Ballmann M, Rohde-Brand F, v d Hardt H. Insulinresistenz: Entscheidender Faktor der Diabetesentstehung bei CF. Monatsschr Kinderheilkd 1996;144:S19.
12. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and β-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab 1994;79:80-5.
13. WHO Study Group. Diabetes mellitus. WHO Tech Rep Series 1985;727:1-113.
14. Lanng S, Thorstelnsson B, Erichsen G, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child 1991;66:612-6.
15. Webb AK, Dodd M, Abbott J, Maddison J. Adult cystic fibrosis: current issues in a regional unit. Respir Med 1993;87:9-15.
16. Dandona P, Hudson ME, Batten JC. B-cell reserve in cystic fibrosis patients and heterozygotes. J Clin Pathol 1983;36:790-7.
17. Skopnik H, Kentrup H, Kusenbach G, Pfaffle R, Kock R. Glukosehomöostase bei zystischer Fibrose. Monatsschr Kinderheilkd 1993;141:42-7.
18. DeSchepper J, Dab I, Derde MP, Loeb H. Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations. Eur J Pediatr 1991; 150:403-6.
19. Hartling SG, Garne S, Binder C, et al. Proinsulin, insulin, and C-peptide in cystic fibrosis after an oral glucose tolerance test. Diabetes Res 1988;7:165-9.
20. Rakotoambinina B, Delaisi B, Laborde K, et al. Insulin responses to intravenous glucose and the hyperglycemic clamp in cystic fibrosis patients with different degrees of glucose tolerance. Pediatr Res 1994;36:667-71.
21. Moran A, Diem P, Klein JD, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991;118:715-23.
22. Leahy JL, Bonner-Weir S, Weir GC. β-cell dysfunction by chronic hyperglycemia: current ideas on mechanism of glucose-induced insulin secretion. Diabetes Care 1992;15:442-54.
23. Abdul-Karim FW, Dahms BB, Velasco ME, Rodman HM. Islets of Langerhans in adolescents and adults with cystic fibrosis. Arch Pathol Lab Med 1986;110:602-6.
24. Soejima K, Landing BH. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus. Pediatr Pathol 1986;6:25-46.
25. Krueger LT, Lerner A, Katz SM, Mack R, Holsclaw DS, Lebenthal E. Cystic fibrosis and diabetes mellitus: interactive or idiopathic? J Pediatr Gastroenterol Nutr 1991;13:209-19.
26. Jiang X, Srinivasan S, Radhakrishnamurthy B, Dalferes ER, Berenson GS. Racial (black-white) differences in insulin secretion and clearance in adolescents: the Bogalusa heart study. Pediatrics 1996;97:357-60.
27. Bergman RN. Toward physiological understanding of glucose tolerance: Minimal-Model approach. Diabetes 1989;38:1512-27.
28. Cucinotta D, de Luca F, Gigante A, et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur J Clin Endocrinol 1994;130:253-8.
29. Lanng S, Thorsteinsson B, Roeder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic tolerance. Clin Endocrinol 1994;41:217-23.
30. Rochat T, Slosman DO, Pichard C, Belli DC. Body composition analysis by dual-energy X-ray absorptiometry in adults with cystic fibrosis. Chest 1994;106:800-5.
31. Rossetti L, Giaccari A, deFronzo RA. Glucose toxicity. Diab Care 1990;12:610-30.
32. vanCauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-77.
33. Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahi S, Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996;39:687-95.
34. Lanng S, Thorsteinsson B, Roder ME, et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired or diabetic glucose tolerance. Acta Endocrinol 1993;128:207-14.
35. Hamdi I, Green M, Shneerson JM, Palmer CR, Hales CN. Proinsulin, proinsulin intermediate and insulin in cystic fibrosis. Clin Endocrinol 1993;39:21-6.
36. O'Rahilly S, Gray H, Humphreys PJ, et al. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995;333:1386-90.
37. Jaspan JB, Mako ME, Kuzuya H, Blix PM, Horwitz DL, Rubenstein AH. Abnormalities in circulating beta cell peptides in chronic renal failure: comparison of C-peptide, proinsulin and insulin. J Clin Endocrinol Metab 1977;45:441-6.
38. Rhodes CJ, Alarcon C. What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 1994;43:511-7.
39. Robbins DC, Tager HS, Rubenstein AH. Biologic and clinical importance of proinsulin. N Engl J Med 1984;310:1165-75.
40. Revers RR, Henry R, Schmeiser L, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 1984;33:762-70.
41. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Verme D. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 1996;45:736-41.
42. Jehle PM, Lutz MP, Fussgänger RD. High affinity binding sites for proinsulin in human IM-9 lymphoblasts. Diabetologia 1996;39: 421-32.